MedTrace Logo

Metabolic Manipulation in Chronic Heart Failure

NCT00841139 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-11-29

No results posted yet for this study

Summary

Conventional measures used for the treatment of chronic heart failure act predominantly by reducing the work performed by the heart. In a recent study, the investigators showed that one drug (perhexiline) substantially improved symptoms and cardiac function in heart failure. The investigators wish to confirm these findings and test whether or not this drug acts by altering the heart's energy source thus augmenting the energetic status and work efficiency of the heart.

Conditions

Interventions

DRUG

Perhexiline

100mg o bd

DRUG

Placebo

1 tablet bd

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • University Hospital Birmingham NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Michael P Frenneaux, MBBS MD · University of Birmingham

  • Roger M Beadle, MBBS · University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841139 on ClinicalTrials.gov